Clinical Trial Update: Tissue and Blood Biomarkers From Patients With Stage III or Stage IV Melanoma Treated With Ipilimumab With or Without Sargramostim

View source ↗

Summary

This trial update summarizes tissue and blood biomarker analyses from patients with stage III/IV melanoma treated with ipilimumab, with or without sargramostim,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• ipilimumab (ipilimumab)
• sargramostim (sargramostim)

Snippet

Sponsor: Eastern Cooperative Oncology Group | Conditions: Melanoma (Skin) | Status: COMPLETED